TIDMPXS
RNS Number : 3723X
Provexis PLC
28 August 2020
28 August 2020
Provexis plc
("Provexis" or the "Company")
Total Voting Rights
Provexis, the business that develops, licenses and sells the
proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient, announces that the issued share capital
of the Company as at today's date comprises 2,070,821,507 ordinary
shares of 0.1 pence each, with equal voting rights. The Company
does not hold any ordinary shares in treasury. Therefore, the total
number of ordinary shares and voting rights in the Company is
2,070,821,507.
The above figure may be used by shareholders in the Company as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
For further information please contact:
Provexis plc Tel: 07490 391888
Ian Ford, CEO enquiries@provexis.com
Dr Niamh O'Kennedy, CSO
Allenby Capital Limited Tel: 020 3328 5656
Nick Naylor / Liz Kirchner
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and
sales of its proprietary, scientifically-proven Fruitflow(R)
heart-health functional food ingredient.
Fruitflow is a natural, breakthrough ingredient that helps with
platelet aggregation. This helps promote normal blood flow and
circulation, which in turn benefits cardiovascular health.
Fruitflow helps the platelets to circulate freely and smoothly
throughout your blood, without sticking to one another or to the
blood vessels themselves. Freely flowing blood helps reduce stress
on your cardiovascular system.
Fruitflow is a highly concentrated form of bioactives which is
lycopene-free and contains over 30 known anti-platelet compounds.
Published clinical studies have shown that Fruitflow works to
maintain healthy blood flow in a similar way to 75mg aspirin but
with a milder and reversible action; Fruitflow has a similar
antiplatelet effect to a single dose of aspirin - but when taken
daily, it has none of aspirin's side effects.
The science behind Fruitflow has been validated by leading peer
review publications and regulatory authorities. Fruitflow is the
only natural antiplatelet to have a health claim approved by the
European Food Safety Authority, stating that 150mg of Fruitflow
'helps maintain normal platelet aggregation, which contributes to
healthy blood flow'.
Provexis plc entered into a long-term Alliance Agreement with
DSM Nutritional Products in 2010 to commercialise Fruitflow through
sales as an ingredient to brand owners in the food, beverage and
dietary supplement categories. More than 90 regional consumer
healthcare brands have now been launched by direct customers of
DSM, and a number of further regional brands have been launched
through DSM's distributor channels.
The Company and DSM have seen an encouraging increase in brand
awareness and customer interest in Fruitflow in recent years, with
an increasing number of further commercial projects being initiated
with prospective customers, including some prospective customers
which are part of global businesses.
Fruitflow has a number of specific health benefits which have
been reflected in three patent filings for:
-- The use of Fruitflow in mitigating exercise-induced
inflammation and for promoting recovery from intense exercise,
seeking to enhance further the potential of the technology in the
sports nutrition sector. Further interest in the role of Fruitflow
in exercise was generated by Team Sunweb Pro Cycling's use of
Fruitflow in the 2018 Tour de France, and the Company is
progressing the formulation and potential launch of a Fruitflow+
nitrates dietary supplement product which was used by Team Sunweb
in the 2019 Tour de France www.fruitflowplus.com/sportrecovery.
-- The use of Fruitflow in managing blood pressure. A pilot
study conducted with the University of Oslo indicated that a 150mg
dose of Fruitflow in powder format significantly lowered the
average 24-hour systolic blood pressure compared to placebo. When
the monitoring time was split into waking and sleeping periods,
both systolic and diastolic blood pressure were significantly lower
after 150mg Fruitflow treatment than after placebo treatment during
the waking period; systolic pressure was also significantly lower
during the sleeping period. The results from the blood pressure
collaboration were published in the International Journal of Food
Sciences and Nutrition and the study is available to view on the
Company's website at:
www.provexis.org/wp-content/uploads/2017/09/IJFSN-Fruitflow-blood-pressure-study-Sep-17.pdf
-- The use of Fruitflow in protecting against the adverse effects of air pollution on the body's cardiovascular system. Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third. The beneficial effects of this reduction can be observed in laboratory models representing healthy subjects as well as in models representing subjects with an underlying cardiovascular problem.
Provexis sells a high quality dietary supplement product
containing Fruitflow and Omega-3 from its separate website
www.fruitflowplus.com on a mail order basis. The product is also
available to purchase from Amazon.co.uk and from Holland &
Barrett.
The Company is working with By-health Co., Ltd, a GBP4bn listed
Chinese dietary supplement business, to support the planned launch
of some Fruitflow based products in the Chinese market. The planned
launch is progressing well with potential sales volumes remaining
at a significant multiple of existing Fruitflow sales.
By-Health has made a significant investment in nine separate
clinical studies in China, at its sole expense, in support of the
Fruitflow based products which it plans to launch in China. The
five studies which have been completed by By-Health showed
excellent results in use for Fruitflow, and provide strong evidence
for By-Health in its regulatory submissions for Fruitflow.
If a successful blue cap health claim is achieved for Fruitflow
in China it would currently be expected to result in some
significant recurring orders for Fruitflow, at a multiple of
current total sales values.
In August 2019 the Company was delighted to announce it had
signed an open-ended collaboration agreement with By-Health, in
support of By-Health's planned launch of Fruitflow based products
in the Chinese market. Project work will be managed and conducted
by Provexis primarily in the UK, with the first project agreed
concentrating on the use of Fruitflow with nitrates in exercise, an
area of considerable commercial interest to By-Health. The
agreement further strengthens the close relationship between
By-Health and Provexis.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com and
www.fruitflowplus.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRUBSSRRBUWUAR
(END) Dow Jones Newswires
August 28, 2020 12:00 ET (16:00 GMT)
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Jan 2024 to Jan 2025
